Carlyle Group, Brighton Park Capital acquire minority stakes in Indegene for $200M biospectrumindia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospectrumindia.com Daily Mail and Mail on Sunday newspapers.
Carlyle, Brighton Park invest $200 million in drug development firm Indegene
The transaction, which is subject to customary regulatory approvals, consists of a secondary sale from existing shareholders of Indegene and a primary investment into the company
PB Jayakumar | February 4, 2021 | Updated 00:25 IST
Global private equity fund Carlyle and US-based Brighton Park Capital have acquired an undisclosed minority stake in Bengaluru-based drug development services and technology provider Indegene for $200 million (Rs 1,461 crore).
The transaction, which is subject to customary regulatory approvals, consists of a secondary sale from existing shareholders of Indegene and a primary investment into the company.
Indegene offers its customers design, build, and manage operations that leverage data and automation to accelerate clinical development and regulatory compliance in biopharma industry. The company claims to have 18 of the top 20 global biopharma organisations as its customer
(2)
Investment will accelerate company s global expansion and consolidate its industry-leading position in healthtech solutions
BANGALORE, India and PRINCETON, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) The Carlyle Group (NASDAQ: CG), Brighton Park Capital and Indegene, the Bangalore-headquartered enterprise healthtech solutions provider, today announced that Carlyle and Brighton Park Capital will acquire minority stakes in the company for US$200 million. The transaction, which is subject to customary regulatory approvals, consists of a secondary sale from existing shareholders of Indegene and a primary investment into the company.
Founded in 1998 by five first-generation entrepreneurs, Indegene has emerged as the leading digital transformation partner to the global life sciences industry. With more than 3,000 employees across North America, Europe, China, Japan and India, Indegene provides technology platforms and commercialization services to pharmaceutical, biotechnology, and med
Carlyle and Brighton Park agree to invest US$200 million in Indegene
Carlyle and Brighton Park agree to invest US$200 million in Indegene
Investment will accelerate company’s global expansion and consolidate its industry-leading position in healthtech solutions
BANGALORE, India and PRINCETON, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) The Carlyle Group (NASDAQ: CG), Brighton Park Capital and Indegene, the Bangalore-headquartered enterprise healthtech solutions provider, today announced that Carlyle and Brighton Park Capital will acquire minority stakes in the company for US$200 million. The transaction, which is subject to customary regulatory approvals, consists of a secondary sale from existing shareholders of Indegene and a primary investment into the company.
Carlyle, Brighton Park to invest $200 m in Indegene
February 02, 2021
To pick up minority stake in healthtech firm via primary, secondary deals The Carlyle Group and Brighton Park Capital will acquire a minority stake in Indegene, a Bengaluru-based enterprise healthtech solutions provider, for $200 million.
The transaction consists of a secondary sale from existing shareholders of Indegene and a primary investment into the company, a press statement from Indegene said.
Founded in 1998 by first-generation entrepreneurs, Indegene is a transformation partner to the global life sciences industry. With more than 3,000 employees across North America, Europe, China, Japan and India, it provides technology platforms and commercialisation services to pharmaceutical, biotechnology and medical device companies.